Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT II: Chemoradiation and Maintenance for Anal Cancer
NCT00025090Phase 3Completed
- Sponsor
- UCL Cancer Institute
- Start
- Mar 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in anal cancer (4 arms), sponsored by UCL Cancer Institute. Primary endpoints: Complete Response Rate at 26 weeks, Acute Toxicity at 4 weeks and 1 more. Started Mar 2001; status: completed.
02
Drugs
cisplatin
03
Conditions
anal cancer
Beyond the preview
Go deeper on NCT00025090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025090.